Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx for the Treatment of Diabetes
NCT05003908Phase 1Terminated
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Nov 2021
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in diabetes mellitus (DM), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Nov 2021; status: terminated.
02
Drugs
AlloRx
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05003908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003908.